Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation

Cardiology Journal

Volumn 23, Issue 3, 2016, Pages 333-343

  Qureshi, Waqas ^a   O’Neal, Wesley T ^a   Soliman, Elsayed Z ^a,b   Al Mallah, Mouaz H ^c,d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Atrial fibrillation; Digoxin; Meta analysis; Mortality; Systematic review

Indexed keywords

DIGOXIN; ANTIARRHYTHMIC AGENT;

ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; DRUG USE; HEART FAILURE; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; HEALTH; SURVIVAL RATE; TRENDS;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DIGOXIN; GLOBAL HEALTH; HUMANS; SURVIVAL RATE;

EID: 84978144243     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2016.0016     Document Type: Review

References (37)

1. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 2014; 130: e272.
2. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010; 31: 2369–2429.
3. Ahmed A, Rich MW, Fleg JL et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation, 2006; 114: 397–403.
4. Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol, 2007; 63: 959–971.
5. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: Report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J, 2007; 28: 2346–2353.
6. Moher D, Liberati A, Tetzlaff J,Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 2009; 6: e1000097.
7. Cochrane handbook for systematic reviews of interventions. 2009. (Accessed at http://handbook.cochrane.org/chap-ter_8/8_3_3_quality_scales_and_cochrane_reviews.htm).
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177–88.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ, 2003; 327: 557–560.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315: 629–634.
11. Moreno SG, Sutton AJ, Ades AE et al. Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Medical Research Methodology, 2009; 9: 2.
12. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol, 2014; 67: 897–903.
13. Duval S TR. A nonparametric “trim and fi ll” method of assessing publication bias in meta-analysis. J Am Statistical Assoc, 2000; 95: 89–98.
14. Hohnloser SH, Connolly SJ, John Camm A, Halperin JL, Radzik D. An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. Europace, 2014; 16: 1117–1124.
15. Whitbeck MG, Charnigo RJ, Khairy P et al. Increased mortality among patients taking digoxin: Analysis from the AFFIRM study. Eur Heart J, 2013; 34: 1481–1488.
16. Gheorghiade M, Fonarow GC, van Veldhuisen DJ et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J, 2013; 34: 1489–1497.
17. Leor J, Goldbourt U, Rabinowitz B et al. Digoxin and increased mortality among patients recovering from acute myocardial infarction: Importance of digoxin dose. The SPRINT Study Group. Cardiovasc Drugs Therapy, 1995; 9: 723–729.
18. Kober L, Torp-Pedersen C, Gadsboll N, Hildebrandt P, Hoilund--Carlsen PF. Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction? Eur Heart J, 1994; 15: 382–388.
19. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol, 1993; 22: 955–962.
20. Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin--converting-enzyme inhibitors. RADIANCE Study. New Engl J Med, 1993; 329: 1–7.
21. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med, 1997; 336: 525–533.
22. Go AS, Mozaffarian D, Roger VL et al. Executive summary: Heart disease and stroke statistics, 2014 update: A report from the American Heart Association. Circulation, 2014; 129: 399–410.
23. Fauchier L, Grimard C, Pierre B et al. Comparison of beta block-er and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol, 2009; 103: 248–254.
24. Freeman JV, Reynolds K, Fang M et al. Digoxin and risk of death in adults with atrial fibrillation: The ATRIA-CVRN Study. Circulation, 2015; 8: 49–58.
25. Tung P, Albert CM. Causes and prevention of sudden cardiac death in the elderly. Nature Rev Cardiol, 2013; 10: 135–142.
26. Marijon E, Le Heuzey JY, Connolly S et al. Causes of death and influencing factors in patients with atrial fibrillation: A competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation, 2013; 128: 2192–2201.
27. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients >/=65 years of age with versus without heart failure. Am J Cardiol, 2014; 114: 401–406.
28. Okin PM, Bang CN, Wachtell K et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circulation, 2013; 6: 243–251.
29. Gjesdal K, Feyzi J, Olsson SB. Digitalis: A dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart, 2008; 94: 191–196.
30. Turakhia MP, Santangeli P, Winkelmayer WC et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: Findings from the TREAT-AF study. J Am Coll Cardiol, 2014; 64: 660–668.
31. Mulder BA, Van Veldhuisen DJ, Crijns HJ et al. Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. Heart Rhythm, 2014; 11: 1543–1550.
32. Washam JB, Lokhnygina Y, Halperin JL et al. Digoxin use in patients with atrial fibrillation is associated with adverse cardiovascular outcomes: Results from the ROCKET AF trial. European Society of Cardiology Annual Sessions. Barcelona, Spain 2014: 4873.
33. Chao TF, Liu CJ, Chen SJ et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide pop-ulation-based cohort study. Canadian J Cardiol, 2014; 30: 1190–1195.
34. Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ. Interaction between Digoxin and Dronedarone in the PALLAS Trial. Circulation, 2014; 7: 1019–1025.
35. Allen LA, Holmes DN, Thomas LE et al. Digoxin use and subsequent outcomes among patients with and without heart failure in a contemporary atrial fibrillation cohort: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation, 2014; 130: e16889.
36. Gamst J, Christiansen CF, Rasmussen BS, Rasmussen LH, Thomsen RW. Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: A population-based cohort study. BMJ, open 2014; 4: e006486.
37. Pastori D, Farcomeni A, Bucci T et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol, 2014; 180C: 1–5.